Recombinant viral vector vaccine

This page covers all Recombinant viral vector vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Filovirus glycoproteins (Ebola virus GP, Marburg virus GP).

Targets

Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)

Phase 3 pipeline (1)

• MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] · Janssen Vaccines & Prevention B.V. · Immunology / Infectious Disease
  MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.

Patent intelligence

• recombinant viral vector vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates